Schwartz TW - Search Results

1

Molecular interaction of a potent nonpeptide agonist with the chemokine receptor CCR8.

Jensen PC, Nygaard R, Thiele S, Elder A, Zhu G, Kolbeck R, Ghosh S, Schwartz TW, Rosenkilde MM. Jensen PC, et al. Among authors: schwartz tw. Mol Pharmacol. 2007 Aug;72(2):327-40. doi: 10.1124/mol.106.035543. Mol Pharmacol. 2007. PMID: 17652183

2

The species selectivity of chemically distinct tachykinin nonpeptide antagonists is dependent on common divergent residues of the rat and human neurokinin-1 receptors.

Jensen CJ, Gerard NP, Schwartz TW, Gether U. Jensen CJ, et al. Among authors: schwartz tw. Mol Pharmacol. 1994 Feb;45(2):294-9. Mol Pharmacol. 1994. PMID: 7509441

3

Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding.

Rosenkilde MM, Cahir M, Gether U, Hjorth SA, Schwartz TW. Rosenkilde MM, et al. Among authors: schwartz tw. J Biol Chem. 1994 Nov 11;269(45):28160-4. J Biol Chem. 1994. PMID: 7525569 Free article.

4

Analysis of selective binding epitopes for the kappa-opioid receptor antagonist nor-binaltorphimine.

Hjorth SA, Thirstrup K, Grandy DK, Schwartz TW. Hjorth SA, et al. Among authors: schwartz tw. Mol Pharmacol. 1995 Jun;47(6):1089-94. Mol Pharmacol. 1995. PMID: 7541509

5

Interaction between the nonpeptide angiotensin antagonist SKF-108,566 and histidine 256 (HisVI:16) of the angiotensin type 1 receptor.

Schambye HT, Hjorth SA, Weinstock J, Schwartz TW. Schambye HT, et al. Among authors: schwartz tw. Mol Pharmacol. 1995 Mar;47(3):425-31. Mol Pharmacol. 1995. PMID: 7700239

6

Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor.

Perlman S, Schambye HT, Rivero RA, Greenlee WJ, Hjorth SA, Schwartz TW. Perlman S, et al. Among authors: schwartz tw. J Biol Chem. 1995 Jan 27;270(4):1493-6. doi: 10.1074/jbc.270.4.1493. J Biol Chem. 1995. PMID: 7829475 Free article.

7

Mutations in transmembrane segment VII of the AT1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists.

Schambye HT, von Wijk B, Hjorth SA, Wienen W, Entzeroth M, Bergsma DJ, Schwartz TW. Schambye HT, et al. Among authors: schwartz tw. Br J Pharmacol. 1994 Oct;113(2):331-3. doi: 10.1111/j.1476-5381.1994.tb16899.x. Br J Pharmacol. 1994. PMID: 7834178 Free PMC article.

8

Evidence for a common molecular mode of action for chemically distinct nonpeptide antagonists at the neurokinin-1 (substance P) receptor.

Gether U, Emonds-Alt X, Brelière JC, Fujii T, Hagiwara D, Pradier L, Garret C, Johansen TE, Schwartz TW. Gether U, et al. Among authors: schwartz tw. Mol Pharmacol. 1994 Mar;45(3):500-8. Mol Pharmacol. 1994. PMID: 8145735

9

Is there a 'lock' for all agonist 'keys' in 7TM receptors?

Schwartz TW, Rosenkilde MM. Schwartz TW, et al. Trends Pharmacol Sci. 1996 Jun;17(6):213-6. doi: 10.1016/0165-6147(96)10017-1. Trends Pharmacol Sci. 1996. PMID: 8763197 Review. No abstract available.

10

Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor.

Hjorth SA, Thirstrup K, Schwartz TW. Hjorth SA, et al. Among authors: schwartz tw. Mol Pharmacol. 1996 Oct;50(4):977-84. Mol Pharmacol. 1996. PMID: 8863844

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

367 results

Search Page

Filters